Synthetic Rubella IgM Serum

Added to your cart

Synthetic Rubella IgM Serum

Cart subtotal: £0.00

View cart (0) Checkout

#SKU SH252-9

£53.51

Price excludes shipping costs.
To view our shipping costs click here.

Need to order this product in bulk?

Contact our team of experts to discuss your bulk requirements

Contact our expert team

Product Details

Perinatal diseases which can be passed from a mother to child are known to cause complications during pregnancy and congenital symptoms at birth. Therefore, a ToRCH screen is often carried out in the first few months of pregnancy, testing for Toxoplasmosis, Rubella, Cytomegalovirus and Herpes Simplex Virus. Traditionally, control solutions are created from the serum of someone suffering with a disease, in this case, someone with Rubella. However, since most people are vaccinated for Rubella at a young age it is often difficult to source a native material. This great alternative to native disease state plasma boasts proven performance, high reproducibility and secure, long term supply.
1ml
SH252-9

More information

Attributes

Description

  • Shipping Information
  • Dry Ice
  • Abbreviations
  • Rubella IgM positive serum
  • Specification
  • >8 S/CO INDEX Rubella IgM
  • Recommended Use
  • Clinical Chemistry, Control Manufacture, Life Science
  • Preservatives
  • N/A
  • Buffer
  • 10mM HEPES, pH 7.5 containing 0.15M NaCl
  • Disease Area
  • Infectious Disease
  • Presentation Matrix
  • Frozen liquid in 10mM HEPES, pH 7.5 containing 0.15M NaCl, filtered through 0.2µm membrane
  • Source
  • human plasma

Technical Documents

Product Information (446.5KB)

Certificates Of Analysis (76.62KB)

Safety Data Sheet (40.06KB)

Sorry, no results found.

Enter the full lot number and hit enter.

BBI Solutions Brands

diarect.png

The acquisition of DIARECT in June 2020 and their world leading recombinant autoimmune antigen capability immediately enhances BBI’s portfolio and position as a ‘complete’ immunoassay reagent supplier. This further enhances BBI’s position as the world’s largest diagnostics components company with a market leading antigen portfolio.

mbs.png

Maine Biotechnology Services brings 27 years of knowledge, experience, process development, and project management to our customers to ensure the best possible antibodies for any application. As antibody development goals in the biotechnology and pharmaceutical industry have evolved the acquisition of MBS will help BBI further meet and exceed our customers needs.

Newsletter

Signup for our newsletter to receive the latest BBI Solutions updates and special offers in your inbox